Evidence map›Paper›PMID 42141171›Full record

ArticlePharmaceutical research2026

Formulation and Evaluation of Indomethacin Nanosuspensions Stabilized by Poly(2-oxazine) and Poly(2-oxazoline)-Based Polymers for Solubility Enhancement.

Erika Espo, Dipti Potdar, Kiana Baas, Larissa Keßler, Mengshi Yang, Kārlis Bērziņš, Marianna Kemell, Topias Kiiskinen, Anni Heinonen, Josef Kehrein and 6 more

Abstract read
In one paragraph

Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Erika EspoDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland. erika.espo@helsinki.fi.
Dipti PotdarDivision of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
Kiana BaasDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
Larissa KeßlerSoft Matter Chemistry, Department of Chemistry, and Helsinki Institute of Sustainability Science, Faculty of Science, University of Helsinki, FI-00014, Helsinki, Finland.
Mengshi YangLehrstuhl Für Chemische Technologie Der Materialsynthese, Department of Chemistry and Pharmacy, Julius-Maximilians-University Würzburg, Röntgenring 11, 97070, Würzburg, Germany.
Kārlis BērziņšDepartment of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2100, Copenhagen, Denmark.
Marianna KemellDepartment of Chemistry, Faculty of Science, University of Helsinki, FI-00014, Helsinki, Finland.
Topias KiiskinenDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
Anni HeinonenDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
Josef KehreinDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
Ben J BoydDepartment of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2100, Copenhagen, Denmark.
Anssi-Pekka KarttunenDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
Leena PeltonenDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
Robert LuxenhoferSoft Matter Chemistry, Department of Chemistry, and Helsinki Institute of Sustainability Science, Faculty of Science, University of Helsinki, FI-00014, Helsinki, Finland.
Alex BunkerDivision of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
Tapani ViitalaDivision of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland. tapani.viitala@helsinki.fi.ORCID http://orcid.org/0000-0001-9074-9450

Funding

Luonnontieteiden ja Tekniikan Tutkimuksen Toimikunta 337660Nordforsk #85352
6 · The paper itself

Abstract

objectiveThe challenges associated with poorly water-soluble drugs have been recognized for several decades. Poor aqueous solubility directly impairs the bioavailability of a drug, but this can be significantly improved using a nanosuspension (NS) formulation strategy. In general, there is high variability in stabilizers that function with different drugs, and it is often difficult to predict which stabilizer will yield a stable NS formulation.

methodsIn this study, poly(2-oxazine)- and poly(2-oxazoline)-based triblock copolymers (P1 and P2) were evaluated and benchmarked against commonly used stabilizers for the preparation of NS formulations, specifically hydroxypropyl methylcellulose and Pluronic F68. This study initiates the validation of P1 and P2 polymers for a new application, as these materials have not been previously studied as stabilizers in oral NS formulations. Indomethacin was selected as a poorly water-soluble model drug for NS preparation using a wet-ball milling technique. The stability of the resulting NSs was monitored over 28 days and their dissolution profiles were assessed under non-sink conditions.

resultsP1 and P2 demonstrated better particle size reduction, and stability properties compared to the traditional stabilizers. In particular, P1 presented a marked improvement in the dissolution profiles of indomethacin, significantly outperforming the other NS formulations and reference samples. Molecular dynamics simulations further revealed distinct differences in the interactions of P1 and P2 with the indomethacin crystal surface, supporting the experimental findings.

conclusionsOverall, our study highlights the potential of P1 as a promising stabilizer for nanosuspensions, providing mechanistic insights into polymer-drug compatibility, improved dissolution performance, and formulation stability.

Indexed as

ExcipientsIndomethacinNanoparticlesOxazinesOxazolesPolymersChemistry, PharmaceuticalDrug CompoundingDrug StabilityPoloxamerSolubilitySuspensionsExcipientsIndomethacinOxazinesOxazolesPoloxamerpoly(2-oxazoline)PolymersSuspensionsdissolution profile and dissolution rate enhancementmolecular dynamics simulationsnanosuspensionnanosuspension stabilitypoly(2-oxazoline) and poly(2-oxazine) polymers

Identifiers

PMID42141171
PMCPMC13269528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.